Protecting retinal cells could save sight

Article

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

A study into the process of retinal cell death could hold the key to stopping a variety of eye diseases that cause blindness, according to a report from a team of researchers from the Yale School of Medicine reported in the journal Investigative Ophthalmology & Visual Science.

The breakdown of retinal cells known as photoreceptors is common to several diseases that cause blindness. In the diseases the researchers studied the photoreceptors were dying from a variety of causes, but common to all cases was the activation of a family of molecules called CREB1/ATF1. The team then attempted to determine if the molecules were contributing to the cell death or were being activated in an attempt to prolong cell life.

Studying retinas treated with a drug known to preserve photoreceptors, the researchers found much higher levels of CREB1/ATF1, suggesting the molecules act as part of the protective mechanism.

"Not only did we find that the drug activated the novel CREB1/ATF1 photoreceptor pathway, but we found that this activation was caused by stress," said Caroline Zeiss, associate professor of comparative medicine and ophthalmology at Yale School of Medicine, USA, in a statement. "This suggests that CREB/ATF1 may be an innate protective response that could be used to achieve broad spectrum preservation of the retina."

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.